Comparison of the effect of the metabolic syndrome and multiple traditional cardiovascular risk factors on vascular function

Mayo Clinic Proceedings

Volumn 87, Issue 10, 2012, Pages 968-975

  Li, Jing ^a,b   Flammer, Andreas J ^a   Lennon, Ryan J ^a   Nelson, Rebecca E ^a   Gulati, Rajiv ^a   Friedman, Paul A ^a   Thomas, Randal J ^a   Sandhu, Nicole P ^a   Hua, Qi ^b   Lerman, Lilach O ^a   Lerman, Amir ^a  

^a MAYO CLINIC   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; RENIN INHIBITOR; TRIACYLGLYCEROL; AUTACOID;

ADULT; AGE DISTRIBUTION; AGED; ANIMAL CELL; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL FUNCTION; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ACTIVITY; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPEREMIA; HYPERTENSION; INFLAMMATION; INSULIN TREATMENT; LEUKOCYTE COUNT; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SMOKING; TONOMETRY; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; VASCULAR ENDOTHELIUM; VASODILATATION; WAIST CIRCUMFERENCE; BLOOD; CARDIOVASCULAR DISEASE; COMORBIDITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE;

ADULT; AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; VASODILATION;

EID: 84871903973     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.07.004     Document Type: Article

References (55)

1. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769-1778.
2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9710):1415-1428.
3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol. 2004;24(8):e149-e161.
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
5. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) study. Circulation. 2002;105(3):310-315.
6. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003.
7. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia. 2009;53(4):600-605.
8. Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008; 371(9628):1927-1935.
9. Kohli P, Greenland P. Role of the metabolic syndrome in risk assessment for coronary heart disease. JAMA. 2006;295(7):819-821.
10. Reilly MP. The metabolic syndrome: more than the sum of its parts? Circulation. 2003;108(13):1546-1551.
11. Johnson LW, Weinstock RS. The metabolic syndrome: concepts and controversy. Mayo Clin Proc. 2006;81(12):1615- 1620.
12. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645.
13. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005;111(3):363-368.
14. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23(2):168-175.
15. Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008;117(19):2467-2474.
16. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research; the Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999;22(5):667-689.
17. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141(12):929-937.
18. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004;44(11):2137-2141.
19. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010; 31(9):1142-1148.
20. Hamburg NM, Larson MG, Vita JA, et al. Metabolic syndrome, insulin resistance, and brachial artery vasodilator function in Framingham Offspring participants without clinical evidence of cardiovascular disease. Am J Cardiol. 2008;101(1):82-88.
21. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81(2):491-497.
22. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24(6):1468-1474.
23. Ferre R, Aragones G, Plana N, et al. High-density lipoprotein cholesterol and apolipoprotein A1 levels strongly influence the reactivity of small peripheral arteries. Atherosclerosis. 2011; 216(1):115-119.
24. Toggweiler S, Schoenenberger A, Urbanek N, Erne P. The prevalence of endothelial dysfunction in patients with and without coronary artery disease. Clin Cardiol. 2010;33(12):746-752.
25. Yim-Yeh S, Rahangdale S, Nguyen AT, et al. Obstructive sleep apnea and aging effects on macrovascular and microcirculatory function. Sleep. 2010;33(9):1177-1183.
26. Lavi S, Prasad A, Yang EH, et al. Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation. 2007;115(20):2621-2627.
27. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010; 31(9):1142-1148.
28. Liuni A, Luca MC, Di Stolfo G, et al. Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in healthy humans. J Am Coll Cardiol. 2011;57(1):93-98.
29. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2010;375(9710):181-183.
30. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23(12):1835- 1839.
31. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42-47.
32. Horiuchi M, Mogi M. C-reactive protein beyond biomarker of inflammation in metabolic syndrome. Hypertension. 2011; 57(4):672-673.
33. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836-843.
34. O'Keefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular diseases: a practical evidencebased approach. Mayo Clin Proc. 2009;84(8):741-757.
35. Ridker PM, Pare G, Parker A, et al. Loci related to metabolicsyndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet. 2008;82(5):1185-1192.
36. Trepels T, Zeiher AM, Fichtlscherer S. The endothelium and inflammation. Endothelium. 2006;13(6):423-429.
37. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009;20(3):182-189.
38. Vu JD, Vu JB, Pio JR, et al. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. Am J Cardiol. 2005;96(5):655-658.
39. Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol. 2005;45(10):1638-1643.
40. Harlan JM, Killen PD, Harker LA, Striker GE, Wright DG. Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment. J Clin Invest. 1981;68(6):1394-1403.
41. Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs- Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest. 2000;80(5):617-653.
42. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002; 296(5577):2391-2394.
43. Cameron AJ, Boyko EJ, Sicree RA, et al. Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity (Silver Spring). 2008;16(12):2707-2716.
44. Galili O, Versari D, Sattler KJ, et al. Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. Am J Physiol Heart Circ Physiol. 2007;292(2):H904- H911.
45. Meyers MR, Gokce N. Endothelial dysfunction in obesity: etiological role in atherosclerosis. Curr Opin Endocrinol Diabetes Obes. 2007;14(5):365-369.
46. Belin de Chantemele EJ, Stepp DW. Influence of obesity and metabolic dysfunction on the endothelial control in the coronary circulation. J Mol Cell Cardiol. 2012;52(4):840-847.
47. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res. 2003;11(11):1278-1289.
48. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
49. Rudofsky G, Roeder E, Merle T, Hildebrand M, Nawroth PP, Wolfrum C. Weight loss improves endothelial function independently of ADMA reduction in severe obesity. Horm Metab Res. 2011;43(5):343-348.
50. Esposito K, Ciotola M, Carleo D, et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care. 2006;29(5):1071-1076.
51. Dandona P. Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein. Mayo Clin Proc. 2008;83(3):333-342.
52. Ferre R, Plana N, Merino J, et al. Effects of therapeutic lifestyle changes on peripheral artery tonometry in patients with abdominal obesity. Nutr Metab Cardiovasc Dis. 2012;22(2):95-102.
53. Kitta Y, Obata JE, Nakamura T, et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol. 2009;53(4):323-330.
54. Rossi R, Nuzzo A, Origliani G, Modena MG. Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women. J Am Coll Cardiol. 2008;51(10):997-1002.
55. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366(9491):1059-1062.